# Prurigo Nodularis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/prurigo-nodularis

> 2 upcoming FDA catalysts in prurigo Nodularis: Dupixent (dupilumab, SNY) on Oct 2027 to Jan 2028 (topline data readout); Dupixent (dupilumab, SNY) on October 2027 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 17, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Prurigo Nodularis | completed | "NCT06366750 (A Study of Barzolvolimab in Patients With Prurigo Nodularis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06366750)) |
| April 17, 2026 | [Rocatinlimab primary completion](https://sec-api.dev/pdufa/rocatinlimab) | AMGN | Prurigo Nodularis | withdrawn | "NCT06527404 (A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-04-17 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06527404)) |
| September 28, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | completed | "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516965)) |
| Sep to Dec 2026 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | scheduled | "NCT06516965 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516965)) |
| Oct 2026 to Jan 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | scheduled | "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516952)) |
| October 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Prurigo Nodularis | delayed | "NCT06516952 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06516952)) |
| Oct 2027 to Jan 2028 | [Dupixent (dupilumab) topline data readout](https://sec-api.dev/pdufa/dupilumab) | SNY | Prurigo Nodularis | scheduled | "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293053)) |
| October 2027 | [Dupixent (dupilumab) primary completion](https://sec-api.dev/pdufa/dupilumab) | SNY | Prurigo Nodularis | scheduled | "NCT06293053 (A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293053)) |

## Drugs

- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Povofortay (povorcitinib)](https://sec-api.dev/pdufa/povorcitinib) (INCY)
- [Dupixent (dupilumab)](https://sec-api.dev/pdufa/dupilumab) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/prurigo-nodularis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Prurigo Nodularis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/prurigo-nodularis

```bibtex
@misc{secapidev_indications_prurigo_nodularis_20261116,
  title        = {Prurigo Nodularis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/prurigo-nodularis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_prurigo_nodularis_20261116","title":"Prurigo Nodularis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/prurigo-nodularis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
